The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Bayer, the manufacturer of Trasylol, has announced that it is removing all remaining Trasylol product from hospital pharmacies and warehouses.  This announcement comes on the heels of a study released in the New England Journal of Medicine found that the use of Trasylol during heart surgery increased the risk of death.  There have been widespread reports of Trasylol being responsible for kidney failure, heart attacks, strokes and death after heart surgery.

This latest report in the New England Journal of Medicine found that patients who received Trasylol during heart surgery faced an 53% increased risk of death compared to two, cheaper alternative drugs.  Trasylol cost almost 10 times these alternative medications and increased the death rate by 53%  Unbelievable.  But at least the manufacturer is doing the right thing now and removing the product from the market.

Many patients who have undergone heart surgery have experienced kidney failure, stroke, heart attack and death.  It is hard for patients or there loved ones to know the culprit since Trasylol is given during the surgery.  Many doctors have deemed these complications as simply risk of heart surgery, but that is not necessarily the case, particularly if Trasylol was administered to control bleeding.

We at InjuryBoard would be happy to speak with you if you want more information on Trasylol.

Comments are closed.

Of Interest